QELBREE 150 mg/1 (Viloxazine Hydrochloride CAPSULE, EXTENDED RELEASE) 150 mg/1

QELBREE 150 mg is an extended-release capsule containing viloxazine hydrochloride, used for managing certain mental health conditions. This medication is designed to provide sustained relief and is manufactured by Supernus Pharmaceuticals, Inc.

Strength

150 mg/1

Pack Size

60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-132-60)

Manufacturer / TM Owner

Supernus Pharmaceuticals, Inc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

QELBREE 150 mg is primarily used for the treatment of attention deficit hyperactivity disorder (ADHD) in adults. Viloxazine hydrochloride, the active ingredient, works to help manage symptoms associated with this condition. People often wonder, 'What is QELBREE used for?' and the answer lies in its ability to support focus and impulse control.

Side Effects

Common effects of QELBREE 150 mg may include changes in appetite, sleep disturbances, and mild gastrointestinal discomfort. Some users report feeling more alert and focused, while others may experience initial adjustments as their body adapts to the medication.

Precautions & Warnings

QELBREE 150 mg should be handled with care, especially if you have a history of heart conditions or high blood pressure. It is important to follow the guidance of a healthcare provider when starting or adjusting your dosage. Always store the medication in a cool, dry place away from children.

Avoid Interactions

QELBREE 150 mg may interact with certain medications, including those that affect liver enzymes. It is advisable to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol and other central nervous system depressants should be used cautiously while taking QELBREE.

Frequently Asked Questions

QELBREE 150 mg is used to manage symptoms of ADHD in adults, helping to improve focus and impulse control.

QELBREE 150 mg is taken orally, typically once daily, and should be swallowed whole with water.

Common side effects may include changes in appetite, sleep disturbances, and mild gastrointestinal discomfort.

It is advisable to use alcohol cautiously while taking QELBREE, as it may interact with the medication.

QELBREE 150 mg can be purchased from licensed online pharmacies or through your healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.